PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 65.08M 5.92M | Sales 2025 * | 471M 42.81M | Capitalization | 1.72B 156M |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.45M | Net income 2025 * | 105M 9.54M | EV / Sales 2024 * | 28 x |
Net Debt 2024 * | 103M 9.33M | Net cash position 2025 * | 61.97M 5.63M | EV / Sales 2025 * | 3.52 x |
P/E ratio 2024 * |
-6.18
x | P/E ratio 2025 * |
8.59
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
CHM | Chairman | 73 | 21-03-31 |
1st Jan change | Capi. | |
---|---|---|
-3.16% | 102B | |
+1.33% | 96.29B | |
+2.13% | 22.18B | |
-15.67% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.70% | 16.36B | |
+5.58% | 13.97B | |
+33.49% | 12.17B |